- GlaxoSmithKline (NYSE:GSK) is now facing corruption claims in Syria, where it's has been accused of bribery to secure business.
- The drugmaker is investigating the claims which date back to 2010 after a whistleblower's email was sent to the company.
- Syria is now the sixth country to be investigated by Glaxo for smaller-scale bribery claims compared to the $480M Chinese allegations which have plagued the company since last July.
- GSK -0.2% AH
at CNBC.com (Nov 14, 2014)